Decreasing Injection Burden for Patients With DME

Show Description +

Dr. Talcott offers an update on the phase 2 VERONA study of EYP-1901, a sustained-release tyrosine kinase inhibitor being evaluated for the treatment of patients with diabetic macular edema.

Posted: 5/19/2026

Keywords:

retina-meeting-recap

•

Diabetic macular edema, DME

•

injection

•

burden

•

VERONA

•

Clinical Trials

•

EYP-1901

•

Eyepoint

•

TKI

•

tyrosine-kinase inhibition

Up Next

Name: Decreasing Injection Burden for Patients With DME
Uploaded: 2026-05-19T16:27:33+00:00
Description: Dr. Talcott offers an update on the phase 2 VERONA study of EYP-1901, a sustained-release tyrosine kinase inhibitor being evaluated for the treatment of patients with diabetic macular edema.

Assessing SHRM With Faricimab Therapy

SriniVas R. Sadda, MD

Using OCT and AI to Evaluate Uveitis

Parisa Emami-Naeini, MD, MPH

Phase 3 Clinical Trial Results for OTX-TKI

Patricio G. Schlottmann, MD

IL-6 Inhibition in Diabetic Macular Edema

Arshad M. Khanani, MD, MA, FASRS, and Roger A. Goldberg, MD

A Potential Noninvasive Therapy for Chronic CSC

Claudio Iovino, MD

An Update on MCO-010 Optogenetics Therapy for Advanced RP

Vinit B. Mahajan, MD, PhD

Back to All Videos

Decreasing Injection Burden for Patients With DME

Katherine E. Talcott, MD

Dr. Talcott offers an update on the phase 2 VERONA study of EYP-1901, a sustained-release tyrosine kinase inhibitor being evaluated for the treatment of patients with diabetic macular edema.

Posted: 5/19/2026

Keywords:

retina-meeting-recap

•

Diabetic macular edema, DME

•

injection

•

burden

•

VERONA

•

Clinical Trials

•

EYP-1901

•

Eyepoint

•

TKI

•

tyrosine-kinase inhibition

Please log in to leave a comment.

Meeting Coverage:

Association for Research in Vision & Ophthalmology

Decreasing Injection Burden for Patients With DME

Up Next

Decreasing Injection Burden for Patients With DME

More From ARVO: 2026 Coverage